Compare THH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THH | INAB |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Japan | United States |
| Employees | 116 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 14.2M |
| IPO Year | N/A | 2020 |
| Metric | THH | INAB |
|---|---|---|
| Price | $0.39 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 924.9K | 71.4K |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $305.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.12 |
| 52 Week High | $56.26 | $4.20 |
| Indicator | THH | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 40.94 |
| Support Level | $0.31 | $1.17 |
| Resistance Level | $0.55 | $2.14 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 36.81 | 12.31 |
Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.